| Literature DB >> 29382301 |
Tom Gyllenhammar1, Mikael Kanski1, Henrik Engblom1, Dirk M Wuttge2, Marcus Carlsson1, Roger Hesselstrand2, Håkan Arheden3.
Abstract
BACKGROUND: Patients with systemic sclerosis (SSc) have high cardiovascular mortality even though there is no or little increase in prevalence of epicardial coronary stenosis. First-pass perfusion on cardiovascular magnetic resonance (CMR) have detected perfusion defects indicative of microvascular disease, but the quantitative extent of hypoperfusion is not known. Therefore, we aimed to determine if patients with SSc have lower global myocardial perfusion (MP) at rest or during adenosine stress, compared to healthy controls, quantified with CMR.Entities:
Keywords: Cardiovascular magnetic resonance imaging; Coronary sinus flow; Microvascular disease; Scleroderma; Systemic sclerosis
Mesh:
Substances:
Year: 2018 PMID: 29382301 PMCID: PMC5791343 DOI: 10.1186/s12872-018-0756-x
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.298
Fig. 1Typical example of coronary sinus delineation (dashed line) in a patient with systemic sclerosis (SSc). Left: Anatomical image; Right: Corresponding phase-contrast image. LA = Left atrium, LV = left ventricle
CMR sequence parameters
| Sequence parameters | Coronary sinus flow | Cine imaging | LGE | |||
|---|---|---|---|---|---|---|
| Philips | Siemens | Philips | Siemens | Philips | Siemens | |
| Repetition time [ms] | 5 | 5 | 2.9 | 2.5 | 4.2 | 8.3 |
| Echo Time [ms] | 2.6 | 2.8 | 1.5 | 1.1 | 1.3 | 3.2 |
| Flip angle [degrees] | 15 | 20 | 60 | 69 | 15 | 25 |
| Inversion/saturation time [ms] | n/a | n/a | n/a | n/a | 220–280 | 300 |
| segmentation factor | 4 | 4 | 17 | 17 | 20 | |
| Aquired spatial res. [mm] | 2.1 × 2.1 × 10 | 1.7 × 1.9 × 8 | 2 × 2 × 8 | 2.2 × 2.2 × 8 | 1.5 × 1.5 × 8 | 1.3 × 1.8 × 8 |
| Reconstructed spatial res. [mm] | 1.1 × 1.1 × 10 | 1.6 × 1.6 × 8 | 1.3 × 1.3 × 8 | 2.2 × 2.2 × 8 | 1.5 × 1.5 × 8 | 1.3 × 1.3 × 8 |
| Aquired temporal res. [ms] | 34 | 40 | 50 | 40 | n/a | n/a |
| Reconstructed time phases | 20 | 20 | 30 | 25 | n/a | n/a |
| SENSE/GRAPPA factor | 2 | 2 | 2 | 2 | 0 | 2 |
| VENC [cm/s] | 80–150 | 80–120 | n/a | n/a | n/a | n/a |
| Number of slices/heartbeat | 1 | 1 | n/a | n/a | n/a | n/a |
| Slice gap [mm] | 0 | 0 | 0 | 0 | 0 | 1.6 |
| Slice thickness [mm] | 10 | 8 | 8 | 8 | 8 | 8 |
LGE late gadolinium enhancement, SENSE sensitivity encoding, GRAPPA generalized autocalibrating partial parallel acquisition, VENC velocity encoding
Fig. 2Typical example of right ventricular insertion point fibrosis marked with arrows in two patients with systemic sclerosis (SSc)
Patient characteristics
| Controls | SSc patients |
| ||
|---|---|---|---|---|
| Age [years] | 62 ± 11 | 61 ± 10 | 0.824 | |
| Sex [n] | female | 10 | 17 | |
| male | 12 | 2 | ||
| BMI [kg/m2] | 25 ± 3 | 26 ± 5 | 0.714 | |
| LVM/BSA [g/m2] | 58 ± 11 | 54 ± 12 | 0.089 | |
| EDV/BSA [ml/m2] | 84 ± 12 | 76 ± 12 | 0.036* | |
| ESV/BSA [ml] | 32 ± 8 | 27 ± 7 | 0.069 | |
| CI [l/min/m2] | 3.2 ± 0.4 | 3.6 ± 0.6 | 0.014 | |
| Skin involvement [n] | diffuse | 7 | ||
| limited | 12 | |||
| Disease duration [years] | 10 ± 6 | |||
| Antibody [n] | ANA | 6 | ||
| ACA | 5 | |||
| ARA | 5 | |||
| ATA | 6 | |||
| PAH [n] | 1 | |||
| VC % expected | 96 ± 12 | |||
| DLCO % expected | 80 ± 19 | |||
| VC % predicted / DLCO % predicted | 1.3 ± 0.3 | |||
| Uric acid [μmol/L] | 262 ± 59 | |||
| Telangiectasias [n] | 14 | |||
| Pitting scars [n] | 5 | |||
| Nailfold capillary density [loops/mm] | 5.0 ± 1.3 | |||
| Skin score < 10 [n] | 18 | |||
| Skin score 10–20 [n] | 1 | |||
| Skin score > 20 [n] | 1 | |||
| Nifedipine [n] | 12 | |||
| ERA [n] | 2 | |||
| PDE5I [n] | 5 | |||
Continues variables are presented as mean ± SD. * P < 0.05
BSA body surface area, BMI Body mass index, LVM left ventricular mass, LV EDV left ventricular end diastolic volume, LV ESV left ventricular end systolic volume, CI cardiac index, PAH pulmonary arterial hypertension, VC vital capacity, DLCO diffusing capacity of the lung for carbon monoxide, ANA anti nuclear antibodies other than ACA, ARA or ATA, ACA anti centromeric antibodies, ARA anti RNA polymerase III antibodies, ATA anti topoisomerase I antibodies, ERA endothelin receptor antagonist, PDE5I phosphodiesterase type 5 inhibitor
Hemodynamic response during adenosine vs. rest
| Controls | SSc patients |
| |
|---|---|---|---|
| Rest | |||
| HR [bpm] | 65 ± 10 | 73 ± 11 | 0.026* |
| Systolic BP [mmHg] | 124 ± 13 | 127 ± 20 | 0.78 |
| Diastolic BP [mmHg] | 73 ± 9 | 71 ± 13 | 0.55 |
| MP [ml/min/g] | 1.1 ± 0.3† | 1.1 ± 0.5 | 0.85 |
| Adenosine stress | |||
| HR [bpm] | 85 ± 15 | 93 ± 13 | 0.05 |
| Systolic BP [mmHg] | 124 ± 17 | 124 ± 19 | 0.70 |
| Diastolic BP [mmHg] | 70 ± 11 | 65 ± 10 | 0.23 |
| MP [ml/min/g] | 4.2 ± 1.3 | 3.1 ± 0.9 | 0.008* |
| CFR | 4.3 ± 1.1† | 3.5 ± 1.9 | 0.09 |
Variables are presented as mean ± SD. * P < 0.05. † N = 18
HR heart rate, BP blood pressure, MP myocardial perfusion, CFR coronary sinus flow reserve (MP stress / MP rest)
Fig. 3Global myocardial perfusion at rest and during adenosine stress for patients with SSc and healthy volunteers. Note the statistically significant difference in myocardial perfusion during stress. The error bars show mean ± SD